Changeflow GovPing Healthcare & Life Sciences Caltech X Chromosome Gene Reactivation Patent E...
Routine Rule Added Final

Caltech X Chromosome Gene Reactivation Patent EP3286310A1

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office granted Patent EP3286310A1 to the California Institute of Technology covering methods for reactivating X chromosome genes. The invention relates to therapeutic and diagnostic applications in genetic medicine, classified under multiple IPC codes including C12N, C12Q, and A61K.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 47 changes logged to date.

What changed

The EPO published patent application EP3286310A1 for Caltech covering methods of reactivating X chromosome genes. The patent names Mitchell Guttman, Chun-Kan Chen, and Colleen A. McHugh as inventors. Designated states include all European Patent Convention contracting states.

Biotechnology and pharmaceutical companies developing gene therapy or genetic diagnostic technologies should review this patent when clearing new products or conducting freedom-to-operate analyses in European markets.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

REACTIVATION OF X CHROMOSOME GENES

Publication EP3286310A1 Kind: A1 Apr 15, 2026

Applicants

California Institute of Technology

Inventors

GUTTMAN, Mitchell, CHEN, Chun-Kan, MCHUGH, Colleen A.

IPC Classifications

C12N 15/11 20060101AFI20181129BHEP C12Q 1/68 20180101ALI20181129BHEP G01N 33/50 20060101ALI20181129BHEP C07H 21/02 20060101ALI20181129BHEP A61K 31/7105 20060101ALI20181129BHEP A61K 38/17 20060101ALI20181129BHEP A61K 39/395 20060101ALI20181129BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Biotechnology research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!